Follow
David E. Nichols
David E. Nichols
Verified email at purdue.edu
Title
Cited by
Cited by
Year
Brine shrimp: a convenient general bioassay for active plant constituents
BN Meyer, NR Ferrigni, JE Putnam, LB Jacobsen, DEJ Nichols, ...
Planta medica 45 (05), 31-34, 1982
72851982
Hallucinogens
DE Nichols
Pharmacology & therapeutics 101 (2), 131-181, 2004
16562004
Psychedelics
DE Nichols
Pharmacological reviews 68 (2), 264-355, 2016
15692016
Functional selectivity and classical concepts of quantitative pharmacology
JD Urban, WP Clarke, M Von Zastrow, DE Nichols, B Kobilka, H Weinstein, ...
Journal of Pharmacology and Experimental Therapeutics 320 (1), 1-13, 2007
13072007
Serotonin receptors
DE Nichols, CD Nichols
Chemical reviews 108 (5), 1614-1641, 2008
12252008
Neural correlates of the LSD experience revealed by multimodal neuroimaging
RL Carhart-Harris, S Muthukumaraswamy, L Roseman, M Kaelen, ...
Proceedings of the National Academy of Sciences 113 (17), 4853-4858, 2016
8672016
Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens
DE Nichols
Journal of psychoactive drugs 18 (4), 305-313, 1986
6701986
Crystal structure of an LSD-bound human serotonin receptor
D Wacker, S Wang, JD McCorvy, RM Betz, AJ Venkatakrishnan, A Levit, ...
Cell 168 (3), 377-389. e12, 2017
4562017
Effects of Schedule I drug laws on neuroscience research and treatment innovation
DJ Nutt, LA King, DE Nichols
Nature Reviews Neuroscience 14 (8), 577-585, 2013
3922013
Effects of enantiomers of MDA, MDMA and related analogues on [3H] serotonin and [3H] dopamine release from superfused rat brain slices
MP Johnson, AJ Hoffman, DE Nichols
European journal of pharmacology 132 (2-3), 269-276, 1986
3761986
Psychedelics as medicines: an emerging new paradigm
DE Nichols, MW Johnson, CD Nichols
Clinical Pharmacology & Therapeutics 101 (2), 209-219, 2017
3472017
Structure of a hallucinogen-activated Gq-coupled 5-HT2A serotonin receptor
K Kim, T Che, O Panova, JF DiBerto, J Lyu, BE Krumm, D Wacker, ...
Cell 182 (6), 1574-1588. e19, 2020
3312020
Serotonergic basis of antipsychotic drug effects in schizophrenia
JA Lieberman, RB Mailman, G Duncan, L Sikich, M Chakos, DE Nichols, ...
Biological psychiatry 44 (11), 1099-1117, 1998
3071998
Characterization of three new psychotomimetics
AT Shulgin, DE Nichols
The psychopharmacology of hallucinogens, 74-83, 1978
2871978
An integrated hypothesis for the serotonergic axonal loss induced by 3, 4-methylenedioxymethamphetamine.
JE Sprague, SL Everman, DE Nichols
Neurotoxicology 19 (3), 427-441, 1998
2691998
Molecular interaction of serotonin 5-HT2A receptor residues Phe339 (6.51) and Phe340 (6.52) with superpotent N-benzyl phenethylamine agonists
MR Braden, JC Parrish, JC Naylor, DE Nichols
Molecular pharmacology 70 (6), 1956-1964, 2006
2532006
trans-10, 11-dihydroxy-5, 6, 6a, 7, 8, 12b-hexahydrobenzo [a] phenanthridine: a highly potent selective dopamine D1 full agonist
WK Brewster, DE Nichols, RM Riggs, DM Mottola, TW Lovenberg, ...
Journal of medicinal chemistry 33 (6), 1756-1764, 1990
2501990
Effects of certain hallucinogenic amphetamine analogs on the release of [3H]-serotonin from rat brain synaptosomes
DE Nichols, DH Lloyd, AJ Hoffman, MB Nichols, G Yim
Journal of medicinal chemistry 25 (5), 530-535, 1982
2441982
Stereochemical effects of 3, 4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H] monoamines into synaptosomes from …
TD Steele, DE Nichols, GKW Yim
Biochemical pharmacology 36 (14), 2297-2303, 1987
2431987
Derivatives of 1-(1, 3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class
DE Nichols, AJ Hoffman, RA Oberlender, P Jacob III, AT Shulgin
Journal of medicinal chemistry 29 (10), 2009-2015, 1986
2211986
The system can't perform the operation now. Try again later.
Articles 1–20